Last reviewed 2026-05-31 · How we verify

Nopoxamine (MYRTECAINE)

Phase 2 active Small molecule ✓ Verified May 2026

Nopoxamine (generic name: MYRTECAINE) is a myrtecaine drug. It is currently in Phase 2 development.

Nopoxamine works by blocking potassium channels in the heart to help stabilize heart rhythm.

Nopoxamine, also known as MYRTECAINE, is a small molecule drug that targets the potassium voltage-gated channel subfamily H member 2. It is classified as a myrtecaine and works by blocking potassium channels, which can help to stabilize heart rhythm. However, its commercial status and approved indications are unknown. As a result, it is not clear if Nopoxamine is patented or available as a generic medication. Further research is needed to determine its safety and efficacy.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MYRTECAINE
Drug class	myrtecaine
Target	Potassium voltage-gated channel subfamily H member 2
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your heart is like a firework, with electrical signals that make it beat. Potassium channels help to calm down these signals, but sometimes they get too excited and cause an irregular heartbeat. Nopoxamine blocks these potassium channels, which helps to slow down the electrical signals and keep the heart beating normally.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nopoxamine CI brief — competitive landscape report
Nopoxamine updates RSS · CI watch RSS

Frequently asked questions about Nopoxamine

What is Nopoxamine?

Nopoxamine (MYRTECAINE) is a myrtecaine drug.

How does Nopoxamine work?

Nopoxamine works by blocking potassium channels in the heart to help stabilize heart rhythm.

What is the generic name of Nopoxamine?

MYRTECAINE is the generic (nonproprietary) name of Nopoxamine.

What drug class is Nopoxamine in?

Nopoxamine belongs to the myrtecaine class. See all myrtecaine drugs at /class/myrtecaine.

What development phase is Nopoxamine in?

Nopoxamine is in Phase 2.

What does Nopoxamine target?

Nopoxamine targets Potassium voltage-gated channel subfamily H member 2 and is a myrtecaine.

Drug class: All myrtecaine drugs
Target: All drugs targeting Potassium voltage-gated channel subfamily H member 2
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing